Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure

NCT07694297 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Decompensation of Liver Cirrhosis
Established Acute-on-Chronic Liver Failure

Interventions

DRUG: NTZ 500mg BID on top of SOC

Sponsor

Genfit